These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 33894014)

  • 1. A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis.
    Miyano T; Irvine AD; Tanaka RJ
    Allergy; 2022 Feb; 77(2):582-594. PubMed ID: 33894014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
    Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
    Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of biologics in atopic dermatitis.
    Wu J; Guttman-Yassky E
    Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologics for Atopic Dermatitis.
    Boguniewicz M
    Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.
    Ratchataswan T; Banzon TM; Thyssen JP; Weidinger S; Guttman-Yassky E; Phipatanakul W
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1053-1065. PubMed ID: 33685604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological Therapies for Atopic Dermatitis: A Systematic Review.
    Zhou S; Qi F; Gong Y; Zhang J; Zhu B
    Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
    Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
    Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
    Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
    J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.
    Butala S; Castelo-Soccio L; Seshadri R; Simpson EL; O'Shea JJ; Bieber T; Paller AS
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1361-1373. PubMed ID: 36948491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
    Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
    Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Emerging Biologics for Atopic Dermatitis.
    Nevid M; Boguniewicz M
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):577-594. PubMed ID: 39389711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-13 antagonists in the treatment of atopic dermatitis.
    Tubau C; Puig L
    Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.
    Yang N; Chen Z; Zhang X; Shi Y
    BioDrugs; 2021 Jul; 35(4):401-415. PubMed ID: 34213742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.